Dr. Anthony J. Reiman
Claim this profileRegional Health Authority B, Zone 2
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
3 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials Anthony J. Reiman is currently running
Lenalidomide +/- Daratumumab
for Multiple Myeloma
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.
Recruiting2 awards Phase 317 criteria
Durvalumab (+/- Tremelimumab)
for Cancer
I238A: The purpose of this study is to find out what effects being treated with durvalumab has on cancer. The researchers doing this study also want to evaluate if prednisone (a type of steroid), when given together with durvalumab, can reduce any side effects. I238B: The purpose of this study is to allow patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)
Recruiting1 award Phase 215 criteria
More about Anthony J. Reiman
Clinical Trial Related5 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Anthony J. Reiman has experience with
- Lenalidomide
- Daratumumab/rHuPH20
- Physical Activity Program
- Health Education Materials
- Durvalumab
- Prednisone
Breakdown of trials Anthony J. Reiman has run
Multiple Myeloma
Plasma Cell Neoplasms
Anxiety Disorders
Colorectal Cancer
Sleep Disorders
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anthony J. Reiman specialize in?
Anthony J. Reiman focuses on Multiple Myeloma and Plasma Cell Neoplasms. In particular, much of their work with Multiple Myeloma has involved treating patients, or patients who are undergoing treatment.
Is Anthony J. Reiman currently recruiting for clinical trials?
Yes, Anthony J. Reiman is currently recruiting for 2 clinical trials in Saint John New Brunswick. If you're interested in participating, you should apply.
Are there any treatments that Anthony J. Reiman has studied deeply?
Yes, Anthony J. Reiman has studied treatments such as Lenalidomide, Daratumumab/rHuPH20, Physical Activity Program.
What is the best way to schedule an appointment with Anthony J. Reiman?
Apply for one of the trials that Anthony J. Reiman is conducting.
What is the office address of Anthony J. Reiman?
The office of Anthony J. Reiman is located at: Regional Health Authority B, Zone 2, Saint John, New Brunswick E2L 4L2 Canada. This is the address for their practice at the Regional Health Authority B, Zone 2.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.